January 13, facing the camera, Indonesian President Joko was vaccinated against the novel coronavirus live.
This is a vaccine developed by China. Indonesian health officials said that the president’s move was to “assure the public that China’s vaccine is safe and effective”.
On the same day, the coronavirus vaccine was promoted nationwide in Indonesia, and at least 180 million people were included in the vaccination plan.
Among them, the first vaccines were put into use from Kexing Biotechnology in China.
Not only Indonesia, but recently, the leaders of Egypt, Turkey, Serbia, Jordan and other countries have taken the lead in vacculating against China.
Serbian President Vučić also joked: “China’s vaccine quality is extremely high, but can it be cheaper?”
In the face of COVID-19, vaccines are regarded as mankind’s greatest hope.
On December 30, 2020, China’s State Food and Drug Administration approved the conditional listing of the State Pharmaceutical Group’s coronavirus vaccine. After that, international orders came in succession–
On the same day, the Ministry of Health of Ukraine reached a procurement agreement with China’s Kochen Biotechnology to purchase 1.91 million doses of vaccines; on the same day, 3 million doses of Kochen Biotechnology vaccines ordered by Turkey arrived in Ankara; the next day, Pakistan announced that it would purchase 1.2 million doses of vaccines from China National Pharmaceutical Group;
On January 3, Thailand’s Ministry of Health announced that it had signed an agreement with Kochen Biotechnology to order 2 million doses of vaccines; on January 6, the President of Peru announced that the first batch of 1 million doses of Chinese medicine vaccines would arrive in Peru; on January 7, Brazil said that it would buy 100 million doses of Kochen Biotechnology’s developed vaccines.
At present, the cumulative number of confirmed cases of COVID-19 worldwide has exceeded 90 million, and hundreds of thousands of new cases are still added every day. The anti-epidemic situation is still grim.
As an important anti-epidemic resource, if the coronavirus vaccine can be fully promoted and inoculated, it will help form herd immunity and reduce the infection rate.
But the international agency “People’s Vaccine Alliance” reveals a reality: high-income countries, which make up 14% of the world’s population, have purchased more than half of the world’s coronavirus vaccines.
Meanwhile, only one in an average of 10 people in 67 low- and middle-income countries is expected to be vaccinated by the end of 2021.
How can the COVID-19 vaccine, which should benefit the vast number of mankind, truly become a “global public health product” that ordinary people can use?
Previously, China solemnly promised that after China’s coronavirus vaccine is completed and put into use, it will make Chinese contributions to the availability and affordability of vaccines in developing countries as a global public health product.
Do what you say. China not only races against time to carry out research and development, but also maintains close communication with WHO and the Global Alliance for Vaccines and Immunization.
It joins the COVID-19 Vaccine Implementation Plan (COVAX) and considers providing vaccines to developing countries in many forms, including donations and pro bono assistance.
Some foreign media said that China’s vaccine will “provide a lifeline” for developing countries.
China’s vaccine has also won the trust of more and more countries because of its research and development results, convenient storage and safety and effectiveness.
In terms of research and development, on April 12, 2020, China Biotechnology, the first clinical trial of the inactivated vaccine against COVID-19 obtained the world and launched phase I and phase II clinical trials simultaneously.
In June, the National Pharmaceutical Group carried out phase III clinical research in the United Arab Emirates, Bahrain, Egypt, Jordan, Peru, Argentina, Morocco and other countries, which is the largest and fastest-growing clinical research of the novel coronavirus vaccine in the world.
At present, more than 10 heads of state and government have been vaccinated against the Chinese bio-coronavirus inactivated vaccine of the State Pharmaceutical Group, and at least more than 50 countries have put forward the demand for purchase.
In terms of storage, Chinese inactivated vaccines can be stored in standard refrigerators at 2-8 °C.
Compared with some countries developing vaccines that require -70°C deep refrigeration, such storage conditions are obviously more convenient.
In response, Reuters said: “Refrigeration at -70°C will pose a huge challenge to transportation and distribution, and areas with short supply of resources such as poor countries may not have equitable access to vaccines.” The Wall Street Journal commented: “Chinese vaccines have obvious advantages in terms of the difficulty of transporting vaccines to the world’s poorest areas.”
From the perspective of safety and effectiveness, according to the data of the Chinese Health Commission, the protection rate of the COVID-19 vaccine of the State Pharmaceutical Group, which is conditionally listed, is 79.34%, and the protection effectiveness meets the standard requirements of WHO and the State Food and Drug Administration.
The incidence of mild fever is less than 0.1%, and the incidence of adverse reactions such as allergy is about Two parts per million; previous research data show that the antibodies produced by vaccines can maintain high levels for more than six months.
Entering 2021, the epidemic is still spreading around the world.
In the face of the major challenges facing human life and health, China’s vaccine production line has been fully powered, striving to make up for the vaccine gap in other countries on the basis of guaranteeing the demand for domestic vaccines.
According to the data of the Ministry of Industry and Information Technology, three enterprises, including the Beijing Institute of Chinese Medicine, the Wuhan Institute and the Beijing Kexing Zhongwei Company, have started the acceleration mode.
Among them, the production capacity of the Beijing Institute of Chinese Medicine Co., Ltd. of Chinese Medicine, has more than 100 million doses at the end of 2020 and more than 1 billion doses by the end of 2021.
Wuhan Institute and Beijing Kexing Zhongwei Company have also completed the construction of vaccine production lines, which will greatly increase production and ensure vaccination demand.
Recently, Feng Duojia, president of the China Vaccine Industry Association, said in an interview that from the overall production capacity level of China’s vaccine industry, there are not too many restrictive obstacles to the large-scale production of COVID-19 vaccines.
Viruses are the common enemy of mankind, and the distribution of vaccines should not be limited by rich and poor, race and geographical. With the release of vaccines to sea, China is constantly fulfilling the promise that “vaccines are the world’s public health products”.